Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lymphoma
Maintenance Treatment in Mantle-Cell Lymphoma Extends Survival
By
Wayne Kuznar
Hematologic Malignancies
,
Lymphoma
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—Maintenance therapy can improve overall survival (OS) in older and younger patients with mantle-cell lymphoma (MCL), based on current experience with rituximab (Rituxan) therapy, but the optimal dose and dosing schedule remain under investigation.
Read Article
Front-Line Treatment of Patients with Advanced Hodgkin Lymphoma
Lymphoma
Front-Line Treatment of Patients with Advanced Hodgkin Lymphoma
Multidrug chemotherapy regimens, with or without radiotherapy, have proved to be highly successful in achieving long-term remissions in the majority of patients with advanced-stage Hodgkin lymphoma. However, depending on the treatment given, approximately 30% of patients with advanced-stage Hodgkin lymphoma do not achieve long-term remission.
Read Article
Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma
By
Wayne Kuznar
Lymphoma
February 2017, Vol 8, No 1
San Diego, CA—Brentuximab vedotin (Adcetris) monotherapy significantly improved the objective response rate (ORR) lasting ≥4 months compared with the investigator’s choice of standard therapy in patients with cutaneous T-cell lymphoma (CTCL), reported Youn H. Kim, MD, Director, Multidisciplinary Cutaneous Lymphoma Clinic, Stanford University School of Medicine, CA, at the 2016 American Society of Hematology meeting.
Read Article
Chemotherapy-Free Induction with Ibrutinib plus Rituximab Shows Unprecedented Efficacy in MCL
By
Charles Bankhead
Lymphoma
February 2017, Vol 8, No 1
San Diego, CA—Combination induction therapy with ibrutinib (Imbruvica) and rituximab (Rituxan) in patients with mantle-cell lymphoma (MCL) led to objective responses in each of the first 50 patients who received this combination in an ongoing, phase 2 clinical trial presented at the 2016 American Society of Hematology meeting.
Read Article
Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma
By
Wayne Kuznar
Lymphoma
February 2017, Vol 8, No 1
San Diego, CA—The PD-1 inhibitor pembrolizumab (Keytruda) has good activity in patients with relapsed or refractory mycosis fungoides or Sézary syndrome, and the responses it produces are deep and durable, according to study results reported by Michael Khodadoust, MD, PhD, Medicine-Oncology, Division of Oncology, Stanford University School of Medicine, CA, at the 2016 American Society of Hematology meeting.
Read Article
Consolidation Therapy After ASCT in Hodgkin Lymphoma: Why and Who to Treat
Hematologic Cancers
,
Lymphoma
Consolidation Therapy After ASCT in Hodgkin Lymphoma: Why and Who to Treat
The combined use of effective multidrug chemotherapy regimens and radiation over the past few decades has led to significant improvements in the prognosis of Hodgkin lymphoma, making achievement of a cure a clinical reality for the majority of patients.
1
With current therapies, long-term tumor control may be achieved in 70%-80% of patients.
1
However, a subset of patients do not respond to frontline therapy or relapses following initial response.
Read Article
CAR T-Cell Therapy Highly Active in Various Lymphomas
Hematologic Malignancies
,
Lymphoma
February 2016, Vol 7, No 1
The use of therapy with chimeric antigen receptor (CAR)-modified T-cells consistently demonstrated activity in advanced hematologic malignancies, including different types of lymphoma, in multiple trials reported at ASH 2015.
Read Article
Checkpoint Inhibitors in Lymphoma: A New Universe
By
Phoebe Starr
Hematologic Malignancies
,
Immunotherapy
,
Lymphoma
,
Personalized Medicine
February 2016, Vol 7, No 1
Immunotherapy is generating great excitement in melanoma and non-small-cell lung cancer (NSCLC). The FDA approvals of checkpoint inhibitors in these tumor types, as well as encouraging preliminary results in other solid tumors, have paved the way for studying these therapies in hematologic cancers.
Read Article
Novel CAR-T Therapy Shows Impressive Results in Aggressive Leukemia, Lymphoma
By
Phoebe Starr
Leukemia
,
Lymphoma
,
Personalized Medicine
February 2014, Vol 5, No 1
New Orleans, LA—Mounting evidence from several research centers shows that autologous T-cells genetically engineered with a chimeric antigen receptor-T (CAR-T; also called CTL019) achieve dramatic responses in patients with advanced leukemia and lymphoma who have exhausted all treatment options.
Read Article
Page 5 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma